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Abstract
Aims: Berberine, a botanical alkaloid purified from Coptidis rhizoma, is reported to activate the AMP-activated protein
kinase (AMPK). Whether AMPK is required for the protective effects of berberine in cardiovascular diseases remains
unknown. This study was designed to determine whether AMPK is required for berberine-induced reduction of oxidative
stress and atherosclerosis in vivo.
Methods: ApoE (ApoE
-/-) mice and ApoE
-/-/AMPK alpha 2
-/- mice that were fed Western diets were treated with berberine for
8 weeks. Atherosclerotic aortic lesions, expression of uncoupling protein 2 (UCP2), and markers of oxidative stress were
evaluated in isolated aortas.
Results: In ApoE
-/- mice, chronic administration of berberine significantly reduced aortic lesions, markedly reduced oxidative
stress and expression of adhesion molecules in aorta, and significantly increased UCP2 levels. In contrast, in ApoE
-/-/AMPK
alpha 2
-/- mice, berberine had little effect on those endpoints. In cultured human umbilical vein endothelial cells (HUVECs),
berberine significantly increased UCP2 mRNA and protein expression in an AMPK-dependent manner. Transfection of
HUVECs with nuclear respiratory factor 1 (NRF1)-specific siRNA attenuated berberine-induced expression of UCP2, whereas
transfection with control siRNA did not. Finally, berberine promoted mitochondrial biogenesis that contributed to up-
regulation of UCP2 expression.
Conclusion: We conclude that berberine reduces oxidative stress and vascular inflammation, and suppresses atherogenesis
via a mechanism that includes stimulation of AMPK-dependent UCP2 expression.
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Introduction
Berberine is an isoquinolone alkaloid found in plants such as
Phellodendron chinense and Coptis chinensis. In traditional Chinese
medicine, berberine from Coptidis rhizoma is used as a constituent of
the herbal medicine Huanglian. In this form it is reported to exert
anti-fungal, anti-bacterial/viral, and anti-oncogenic effects, as well
as a beneficial effect on diabetes [1,2,3,4,5], and anti-atherogenic
properties [6,7,8]. Berberine has also been reported to reduce the
incidence of cardiovascular diseases [9,10,11]. Several mecha-
nisms are reported to be associated with the beneficial properties
of berberine including improvement of endothelial function and
dyslipidemia, inhibition of low-density lipoprotein oxidation, and
decreased blood pressure. However, the molecular targets through
which berberine exerts its beneficial effects are undefined.
AMP-activated protein kinase (AMPK) is a heterotrimer
consisting of a, b, and c subunits, which each have at least two
isoforms. The a subunit contains the catalytic site, but all subunits
are necessary for full activity. An increase in the ratio of AMP/
ATP activates AMPK by a number of mechanisms, including
direct allosteric activation and covalent modification in which an
AMP-dependent AMPK kinase (AMPKK) phosphorylates the a
subunit on Thr172. AMPK is generally quiescent under normal
conditions but is activated in response to signals and stresses that
increase the AMP/ATP ratio, such as hypoglycemia, strenuous
exercise, anoxia, and ischemia. Once activated, AMPK switches
on catabolic pathways that generate ATP, while switching off
ATP-consuming processes (e.g., biosynthesis, cell growth, and
proliferation), and in doing so acts as an ‘‘energy gauge’’. This
homeostasis function is regarded as a fundamental feature of
multiple AMPK-mediated biological processes [12].
Although the effects of AMPK on key metabolically relevant
organs and tissues such as liver, skeletal muscle, adipose tissue, and
hypothalamus have been relatively well documented [13], the
notion that AMPK activation could be used to promote vascular
health has only recently emerged. For example, in vascular tissues
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the beneficial effects of several interventions including physical
exercise [15], statins, thiazolidinediones (TZDs) [16], leptin
[17,18], adiponectin [19,20,21], and rosiglitazone in diabetes
[22,23,24]. AMPK is also important for maintaining endothelial
cell nitric oxide (NO) activity and endothelial function via the
AMPK-endothelial nitric oxide synthase (eNOS)-NO axis [25].
Moreover, AMPK activation might indirectly improve vascular
endothelial function by improving metabolic profiles and insulin
sensitivity [26,27,28].
Recent studies, including studies from our group, have shown
that berberine causes a dose- and time-dependent activation of
AMPK in cultured endothelial cells [29,30,31]. In isolated aortas,
berberine-dependent AMPK activation improves endothelium-
dependent vasorelaxation, likely via AMPK-dependent phosphor-
ylation of endothelial nitric oxide synthase [32]. Although
beneficial effects of berberine in cardiovascular diseases have been
reported [10,33], to date no study has examined the effects of
chronic administration of berberine on atherosclerosis in vivo.
Furthermore, it is important to determine whether AMPK
activation is required for anti-atherosclerotic effects of berberine
in vivo in order to comprehensively elucidate its properties. The
present study investigated the effects of berberine on atheroscle-
rosis and the relative contributions of AMPK alpha 2 in berberine-
induced suppression of atherosclerotic lesions.
Materials and Methods
Materials
Antibodies against phospho-AMPK, intercellular adhesion
molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1,
4-hydroxy-trans-2-nonenal (4-HNE), 3-nitrotryosine (3-NT) and
b-actin were obtained from Cell Signaling Biotechnology
(Danvers, MA). Antibodies against uncoupling protein (UCP) 2
were obtained from Fitzgerald Industries International, Inc.
(Acton, MA). Nuclear respiratory factor (NRF)1 and mitochon-
drial transcription factor A (mtTFA) antibodies, and the specific
siRNA for AMPK were purchased from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA). AICAR was from Toronto Research
Chemicals Inc. (North York, ON, Canada), and all other
chemicals, unless indicated, were purchased from Sigma-Aldrich
(St. Louis, MO).
Animals
Mice were housed in temperature-controlled cages under a 12-h
light-dark cycle with free access to water and either regular rodent
diet ad libitum or a modified pro-atherogenic diet as indicated.
AMPK alpha 2
-/- mice [5,34] that had been backcrossed onto a
wild-type C57BL/6 background were crossed with C57BL/6
ApoE
-/- mice (The Jackson Laboratory, Bar Harbor, ME) to
generate ApoE
-/-/AMPK alpha 2
-/- mice. Accelerated atheroscle-
rosis was induced by feeding the mice a Western diet containing
0.21% cholesterol and 21% fat (D12079B, Research Diets Inc,).
This diet was administered beginning at 5 weeks of age and
continued for 8 consecutive weeks. At 5 weeks of age, berberine
(Sigma-Aldrich) was also added to the drinking water (1 mmol/L)
for 8 weeks. The animal protocol (10-142H) was reviewed and
approved by the University of Oklahoma Institutional Animal
Care and Use Committee (IACUC).
Cell culture
Human umbilical vein endothelial cells (HUVECs) obtained
from ATCC (Manassas, VA) were grown in Eagle basal medium
(Clonetics Inc, Walkersville, MD) supplemented with 5% fetal
bovine serum (FBS), penicillin (100 mg/mL), and streptomycin
(100 mg/mL). Cells between passages 3 and 8 were used in all
experiments. Cells were incubated at 37uC in a humidified
atmosphere of 5% CO2 and 95% air, and grown to 70% to 80%
confluence before being treated with the indicated agents.
Determination of serum cholesterol, triglyceride, and
blood glucose levels
Blood glucose levels from non-fasting mice were determined by
applying tail blood to an OneTouch Ultra Blood Glucose
Monitoring System (LifeScan). Serum cholesterol and triglyceride
levels were measured enzymatically, using Infinity reagents
(Thermo DMA) according to the manufacturer’s instructions.
Atherosclerotic lesion analysis
After being fed a Western diet for 8 weeks, mice were
anesthetized and euthanized. The heart and aortic tissue were
removed from the ascending aorta to the iliac bifurcation and
placed in 4% paraformaldehyde for 16 h. For analysis of the lesion
area in the aortic arch, the intimal surface was exposed by a
longitudinal cut from the ascending arch to 5 mm distal of the left
subclavian artery to allow the lumen of the aortic arch to be laid
flat. The aorta was rinsed for 5 min in 75% ethanol, stained with
0.5% Sudan IV in 35% ethanol and 50% acetone for 15 min,
destained in 75% ethanol for 5 min, and then rinsed with distilled
water. Digital images of the aorta were captured under a
stereomicroscope, and the lesion area was quantified from the
aortic arch to 5 mm distal of the left subclavian artery using Alpha
Ease FC software (version 4.0 Alpha Innotech). To evaluate
plaque formation in other parts of the aorta, 8-mm-thick cross-
sections of atherosclerotic lesions from the proximal aorta were
stained with hematoxylin and eosin after fixation in 4%
paraformaldehyde.
Immunocytochemistry staining
Immunocytochemistry staining and analysis of aortic lesions
were performed as described previously [35].
Real-time PCR analysis
Total mRNA was isolated from HUVECs using the QIAGENH
RNeasyH Mini kit. UCP2 mRNA was quantified by real-time
PCR as described previously [36].
Western blot analysis
Cell lysates and tissue homogenates were subjected to Western
blot analysis as described previously [37].
Statistics
Results were analyzed with a one-way ANOVA with appropri-
ate post-hoc analysis of results and Student’s t test. Values were
expressed as mean 6 SE. A p value less than 0.05 was considered
statistically significant.
Results
Chronic administration of berberine significantly
attenuates aortic lesions in ApoE
-/- mice but not AMPK
alpha 2
-/-/ApoE
-/- mice
ApoE
-/- mice are known to develop a robust aortic atheroscle-
rotic phenotype when fed a Western diet [38]. Therefore, we first
evaluated the effects of berberine on the severity of aortic
atherosclerosis in ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice
maintained on this diet. ApoE
-/-/APMK alpha 2
-/- mice
AMPK and UCP2 in Atherosclerosis
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-/- mice (Fig. 1A-C).
Interestingly, berberine treatment significantly reduced the
severity of atherosclerotic lesions in the aortic arch of ApoE
-/-
mice. The aortic lesion-mitigating effect of berberine was less
strong in ApoE
-/-/APMK alpha 2
-/- mice than in ApoE
-/- mice
(Fig. 1A–C), suggesting that APMK alpha 2 is critical for the anti-
atherosclerotic effects of berberine in ApoE
-/- mice.
Berberine increases the phosphorylation of AMPK at
Thr172 and acetyl-CoA carboxylase (ACC) at Ser79 in
ApoE
-/-aortas
The observation that berberine had a smaller effect on aortic
lesions in ApoE
-/-/AMPK alpha 2
-/- mice prompted us to
determine whether berberine activates AMPK in the affected
areas of the aorta. Because Thr172 phosphorylation of AMPK is
closely associated with AMPK activation and can be used as an
index for AMPK activity [25], we first monitored the levels of
AMPK-Thr172 phosphorylation in aortic tissue from vehicle- or
berberine-treated ApoE-/- mice using immunocytochemical (IHC)
staining. Berberine markedly increased the level of p-AMPK
staining in aortic tissues from ApoE
-/- mice, but did not increase
staining in aortic tissues from ApoE
-/-/AMPK alpha 2
-/- mice
(Fig. 1D).
Acetyl CoA carboxylase (ACC) is a well-characterized substrate
of AMPK in endothelial cells, and phosphorylation of ACC at
Ser79 reflects AMPK activity in tissues [39]. We monitored p-
ACC levels in aortic tissues from both ApoE
-/- and ApoE
-/-/
AMPK alpha 2
-/- mice. In accord with the p-AMPK findings,
berberine treatment markedly increased the levels of p-ACC in
ApoE
-/- mice, but not in ApoE
-/-/AMPK alpha 2
-/- mice (Fig. 1E).
Overall, these data suggest that berberine activates AMPK in
atherosclerotic aortic tissues.
Effects of berberine on serum cholesterol, triglycerides,
and glucose
We next determined if chronic berberine administration alters
the levels of lipids and glucose, which exert effecs on atheroscle-
rotic lesions. As shown in Table 1, typical metabolic parameters
(blood glucose, serum cholesterol, and triglyceride) did not differ
between ApoE
-/-/AMPK alpha 2
-/- mice and ApoE
-/- mice. In
addition, berberine treatment did not affect the levels of blood
glucose, cholesterol, and triglyceride in ApoE
-/- mice or ApoE
-/-/
AMPK alpha 2
-/- mice (Table 1).
Berberine attenuates expression of adhesion molecules
VCAM-1 and ICAM-1 in aortic atherosclerosis lesions in
vivo
The expression of the adhesion molecules intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) in endothelial cells is the earliest known event in the
Figure 1. AMPK-dependent reduction of aortic lesions by berberine in vivo. A. Representative images of aortic arch lesion in ApoE
-/- and
ApoE
-/-/AMPK alpha 2
-/- mice fed a HFD. Berberine reduced the size of lesions in both ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice. B. Aortic arch
atherosclerotic lesions were measured as percentage of luminal diameter in ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice with or without berberine
treatment. *p,0.05 ApoE
-/- vs. ApoE
-/-/AMPK alpha 2
-/-, # p,0.05 berberine vs. vehicle. n=7 or 8 for each group. C. Proximal aorta section showing
atherosclerotic lesions. Shown are representative cross-sections from serial sections of proximal aorta visualized by hematoxylin and eosin staining. In
each group, 4–5 mice were evaluated and displayed similar phenotypes. D&E. Aortic sections from ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice fed a
HFD were immunohistochemically probed with antibodies specific for p-AMPK and p-ACC. n=7 or 8 for each group.
doi:10.1371/journal.pone.0025436.g001
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whether berberine might act upstream of that event, we assayed
the levels of VCAM-1 and ICAM-1 in aortic lesions isolated from
berberine-treated ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice.
Both VCAM-1 (Fig. 2A) and ICAM-1 (Fig. 2B) were highly
expressed in the sections of aortic root atherosclerotic lesions
harvested from ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice fed
the pro-atherogenic diet. However, ApoE
-/- animals that had been
treated with berberine exhibited significant abrogation of VCAM-
1 expression in aortic tissue, whereas ApoE
-/-/AMPK alpha
2
-/-mice did not (Fig. 2A). Berberine treatment attenuated ICAM-
1 staining in ApoE
-/- mice, but did not affect ICAM-1 staining in
the ApoE
-/-/AMPK alpha 2
-/- mice (Fig. 2B).
Berberine reduces 4-hydroxy-2-enal (4-HNE) and 3-
nitrotyrsoine in aortic atherosclerotic plaques in vivo
Oxidative damage to polyunsaturated lipids can give rise to
potent cytotoxic compounds including several c-hydroxy-a, b-
unsaturated aldehydes. An important example of these aldehydes
is 4-HNE, which is thought to play an important role in
atherogenesis [42]. We examined whether berberine treatment
affected the levels of 4-HNE in aortic atherosclerosis using IHC
staining. As expected, lesions sectioned from ApoE
-/- animals had
strong immunostaining for 4-HNE (Fig. 3A). 4-HNE staining was
notably stronger in ApoE
-/-/AMPK alpha 2
-/- aortas implying
that the AMPK alpha 2 isoform is required to protect the
endothelium from damaging effects of this aldehyde. In ApoE
-/-
mice, but not ApoE
-/-/AMPK alpha 2
-/- mice, the immunostain-
ing for 4-HNE was significantly reduced by berberine treatment.
To further support the notion that peroxidation-based stress is
involved in atherogenesis in these animals, we used IHC techniques
to probe the aortic lesions for malondialdehyde (MDA), a
commonly used marker of peroxidation. MDA expression was
robustly evident in both ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/-
lesions. Berberine markedly attenuated MDA staining in ApoE
-/-
lesions, but not ApoE
-/-/AMPK alpha 2
-/- lesions (Fig. 3B).
Nitration of protein tyrosines is considered a ‘‘footprint’’ of
reactive nitrogen species including peroxynitrite. To further
establish the effects of berberine on oxidative stress, we monitored
the levels of 3-nitrotyrosine (NT)-modified proteins in aortas.
Intense NT staining was found in aortas harvested from both
ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- (Fig. 3C). Berberine
treatment abrogated 3-NT staining in ApoE-/- lesions but not in
ApoE
-/-/AMPK alpha 2
-/- lesions. These data reinforce the notion
that the effects of berberine on oxidative stress rely on the AMPK
alpha 2 isoform.
Berberine-enhanced UCP2 expression is AMPK alpha 2-
dependent in vivo
Uncoupling protein 2 (UCP2) is critically involved in mitigating
oxidative stress in the endothelium [43]. Earlier work from our
group established that AMPK regulates the expression of UCP2 in
endothelial cells [36]. Because mitochondrial uncoupling via
UCP2 appears to play a critical role in rodent models of
atherogenesis [36,44], we determined whether berberine treat-
ment up-regulates UCP2 expression. If so, that result would
implicate UCP2 in the mechanism of berberine suppression of
oxidative stress and vascular inflammation. UCP2 expression was
Table 1. Serum cholesterol, triglyceride, blood glucose and
body weight in ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice.
ApoE
-/- ApoE
-/-/AMPK alpha 2
-/-
Vehicle Berberine Vehicle Berberine
Body weight (g) 25.561.9 26.861.3 28.962.7 27.561.5
Cholesterol (mmol/l) 29.563.6 23.460.8 29.563.0 26.661.1
Triglyceride (mmol/l) 1.5360.34 1.1560.12 1.1960.29 0.9760.14
Glucose (mg/dl) 224625.6 231616.2 178.7616.9 170.3616.2
Values are mean 6 SE. n=7-8 per group. Blood glucose levels were determined
by applying tail blood from non-fasting mice to a One touch Ultra Blood
Glucose Monitoring System (LifeScan). Serum cholesterol and triglyceride levels
were measured enzymatically using Infinity reagents (Thermo DMA) according
to the manufacturer’s instructions.
doi:10.1371/journal.pone.0025436.t001
Figure 2. Berberine reduces VCAM-1 and ICAM-1 expression in ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice. IHC was performed on
sections of aortic arch atherosclerotic plaques harvested from ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice fed a HFD. Sections were immunostained
with antibodies specific for VCAM-1 (A) and ICAM-1 (B). *p,0.05 ApoE
-/- vs. ApoE
-/-/AMPK alpha 2
-/-, #p,0.05 berberine vs. vehicle. n=7 or 8 for
each group.
doi:10.1371/journal.pone.0025436.g002
AMPK and UCP2 in Atherosclerosis
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25436almost absent in vehicle-treated ApoE
-/- or ApoE
-/-/AMPK alpha
2
-/- mice (Fig. 4). Berberine treatment significantly increased
UCP2 staining in ApoE
-/- lesions, but not in ApoE
-/-/AMPK
alpha 2
-/- lesions. Interestingly, berberine-enhanced UCP2
expression was evident in the endothelial layers and not in the
sub-endothelial structures or tunica media, suggesting that the
effect of berberine is relatively specific for endothelial cells and the
tunica intima of the vasculature.
Berberine increases UCP2 expression via AMPK activation
Although AMPK is functionally active in several vascular cells
including endothelial cells, macrophages, and vascular smooth
muscle cells and berberine might exerts anti-atherosclerotic effects
by suppressing the functions of macrophages and vascular smooth
muscle cell, we employed endothelial cells to determine the
contribution of AMPK activation to berberine induction of UCP2
expression. We performed siRNA-mediated silencing of the two
Figure 3. Berberine reduces oxidant stress in vivo. Berberine blocked expression of 4-HNE (A), MDA (B) and 3-NT (C) in aortic atherosclerotic
plaques from ApoE
-/- mice but not ApoE
-/-/AMPK alpha2
-/- mice. IHC was performed on sections of the aortic arch atherosclerotic plaques harvested
from ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice fed a HFD. Sections were immunostained with antibodies specific for 4-HNE (A), MDA (B) or 3-NT (C).
*p,0.05 ApoE
-/- vs. ApoE
-/-/AMPK alpha 2
-/-, #p,0.05 berberine vs. vehicle. n=7 or 8 for each group.
doi:10.1371/journal.pone.0025436.g003
Figure 4. Berberine increases UCP2 expression in ApoE
-/- but not ApoE
-/-/AMPK alpha 2
-/- mice. IHC was performed on sections of the
aortic arch atherosclerotic plaques harvested from ApoE
-/- and ApoE
-/-/AMPK alpha 2
-/- mice fed a HFD. Sections were immunostained with antibodies
specific for UCP2. *p,0.05 ApoE
-/- vs. ApoE
-/-/AMPK alpha 2
-/-, #p,0.05 berberine vs. vehicle. n=7 or 8 for each group.
doi:10.1371/journal.pone.0025436.g004
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in HUVECs. As expected, transfection of either AMPK alpha 1
siRNA or AMPK alpha 2 siRNA down-regulated AMPK alpha 1
or AMPK alpha 2 expression (Figure 5A). Importantly, transfec-
tion of either AMPK alpha 1- or AMPK alpha 2-specific siRNAs
abolished berberine-induced UCP2 expression, whereas a control
siRNA had no effect.
We also directly assayed UCP2 mRNA in HUVECs using real-
time PCR. After treatment with berberine, the level of UCP2
mRNA was 2.4-fold higher than in untreated cells. Real-time
PCR results also indicated that both AMPK alpha 1 and AMPK
alpha 2 siRNAs reduced the up-regulation of UCP2 mRNA by
berberine (Fig. 5B). These data imply that AMPK mediates the
induction of UCP2 transcription and protein expression by
berberine.
AMPK activation increases UCP2 transcription
We next examined the mechanism by which AMPK activation
alters UCP2 expression in cultured endothelial cells. To further
define the effects of AMPK on UCP2 expression, HUVECs were
incubated with several structurally unrelated AMPK activators
including aminoimidazole carboxamide ribonucleotide (AICAR),
metformin, and berberine. AICAR and metformin increased
UCP2 expression 2-fold after 2 h treatment (Fig. 6A). Moreover,
both AICAR and berberine increased UCP2 mRNA levels.
Rosiglitazone, a peroxisome proliferator-activated receptors
(PPARs) agonist, was employed as a positive control because it
is known to increase UCP2 mRNA levels [45] (Fig. 6B). Pre-
treatment of HUVECs with the transcription inhibitor actino-
mycin D dramatically reduced AICAR-enhanced UCP2 expres-
sion (Fig. 6C). Similarly, cycloheximide, a protein translation
inhibitor, significantly inhibited both berberine- and AICAR-
induced UCP2 expression (Fig. 6D). Overall, these data suggest
that AMPK-dependent regulation of UCP2 expression by
berberine is mediated by effects on both transcription and
translation.
NRF1 is required for AMPK-dependent upregulation of
UCP2
The transcription factor NRF1 plays an important role in
regulating key genes required for mitochondrial respiratory
function and in promoting mitochondrial biogenesis to accompany
with up-regulation of UCP2 [46,47]. We used siRNA silencing to
investigate whether NRF1 is required for AMPK-mediated UCP2
expression in HUVECs. Interestingly, we found that berberine
increased NRF1 expression in the control siRNA group,
suggesting that berberine regulates NRF1 (Fig. 6E). Transfection
of NRF1 siRNA, but not control siRNA, ablated the up-regulation
of UCP2 protein by berberine, suggesting that AMPK-dependent
UCP2 expression might require NRF1.
Berberine increases markers of mitochondrial protein
synthesis and UCP2 translocation
The discovery that UCP2 expression was up-regulated by
berberine treatment led us to examine whether other critical
mitochondrial proteins might also be affected by berberine. We
therefore investigated whether berberine increased the synthesis of
other mitochondrial proteins in HUVECs by comparing protein
levels in mitochondrial and cytoplasmic fractions. Berberine-
induced UCP2 expression was observed in the mitochondrial
fraction but not in the cytoplasm, as expected (Fig. 7A). Berberine
also increased the expression of cytochrome C oxidase, which is
encoded in mitochondrial DNA and induced by mtTFA, a
mitochondria-specific transcription factor. The AMPK activator
AICAR also increased cytochrome C oxidase and UCP2
expression in the mitochondrial fraction (Fig. 7B). This set of
data suggests that berberine stimulates mitochondrial biogenesis
via AMPK activation.
We also examined whether mitochondrial biogenesis might
promote the apparent upregulation of UCP2 protein levels in the
mitochondria by increasing UCP2 translocation from the nucleus,
where it is encoded, to the mitochondrion where it acts. Pre-
treatment of HUVECs with chloramphenicol, an inhibitor of
Figure 5. AMPK inactivation abolishes UCP2 mRNA and protein expression in HUVECs. A. Immunoblot analysis of UCP2 in berberine-
induced HUVECs transfection with AMPK alpah1 and alpha 2 siRNA. HUVECs were transfected with control siRNA or siRNA specific to AMPK alpha 1 or
AMPK alpha 2 for 48 h then stimulated by berberine (10 mmol/L) for 2 h. Cells lysates were subjected to Western blot analysis using antibody against
AMPK alpha1, AMPK alpha 2, UCP2 and b-actin (n=3; *p,0.05 vehicle vs. berberine treatment, # p,0.05 control siRNA vs. AMPK alpha 1 or alpha 2
siRNA). B. Quantitative PCR analysis of UCP2 mRNA in HUVECs treatment with berberine. HUVECs were infected with AMPK alpha 1, alpha 2 siRNA or
control siRNA for 48hthen stimulated by berberine (10 mMol/L). Total mRNA was isolated by according to manufacturer’s instructions (QIAGEN). UCP2
mRNA was quantified by real-time PCR. (n=4; *p,0.05 vehicle vs. berberine treatment, # p,0.05 control siRNA vs. AMPK alpha 1 or alpha 2 siRNA).
doi:10.1371/journal.pone.0025436.g005
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induced UCP2 expression (Fig. 7C). This finding lends strength to
the notion that UCP2 translocation was inhibited in the HUVEC
assay.
mtTFA is a known mitochondrial transcription factor that
controls mitochondrial DNA transcription [48]. Transfection of
HUVECs with mtTFA-targeted siRNA, but not control siRNA,
dramatically reduced the berberine-induced increase in UCP2
expression (Fig. 7D). Also, berberine induction of mtTFA
expression was observed as early as 30 min after berberine
treatment, suggesting that mitochondrial biogenesis is promoted
by berberine (Fig. 7E).
Discussion
The salient and novel finding of this study is that berberine
appears to manifest its anti-atherogenic properties via AMPK-
dependent ROS suppression, likely via increased expression of
UCP-2. Further, we found that AMPK-enhanced UCP2 expres-
sion was mediated by NRF1. This finding is consistent with our
recent report that the a2 subunit of AMPK is critical for mitigating
ER stress and protecting from atherosclerosis in vivo [49]. Our
results are in line with previous reports that AMPK activation by
S17834, a polyphenol, suppresses atherosclerosis caused by
diabetes in LDL receptor (LDLr) knockout mice [50] and that
ApoE
-/-/AMPK alpha 2
-/- mice display accelerated development
of high-fat diet-induced aortic lesions.
UCP2 is a mitochondrial transporter present in the inner
membrane of mitochondria and belongs to the family of anion
mitochondrial carriers. The absence of UCP2 in mice has been
reported to increase oxidant stress [51,52] and to amplify the
development of atherosclerotic plaques [53]. Increasing evidence,
summarized below, supports a role for UCP2 as a modulator of
mitochondria-derived reactive oxygen species (ROS) [54,55].
UCP2 is reported to reduce ROS not only in the mitochondria,
but within the whole cell and even in the extracellular space
[43,56,57]. A recent report indicates that UCP2-mediated
uncoupling in endothelial cells can decrease extracellular ROS
when co-incubated with low-density-lipoproteins (LDL) [43,58]. In
leptin-deficient ob/ob mice, diminished UCP2 levels and increased
mitochondrial ROS production relative to normal mice are found
in conjunction in macrophages [59]. UCP2
-/- mice [52] and
Figure 6. Inhibition of transcription attenuates AMPK-induced UCP2 mRNA and UCP2 protein in HUVECs. A. Effects of AICAR,
metformin and berberine on UCP2 expression in HUVECs. n=3; *p,0.05, vehicle vs. treatment. B. Quantitative PCR analysis of UCP2 mRNA levels in
confluent HUVECs treated with AICAR (for 1 h), berberine (for 1 h) or Rosiglitazone (for 24 h). Total mRNA was isolated and UCP2 mRNA was
quantified by real-time PCR compared with GAPDH. n=4; *p,0.05, vehicle vs. treatment. C. Effect of actinomycin D on up-regulation of UCP2 by
berberine. Confluent HUVECs were pretreated with actinomycin D (10 mg/ml) for 1 h, then treated with berberine or AICAR for 2 h. Cell lysates were
subjected to Western blot analysis using antibody against UCP2 and b-actin. The blot is a representative of three blots from three independent
experiments. D. Effect of cycloheximide on expression of UCP2 by berberine and AICAR. Confluent HUVECs were pretreated with cycloheximide
(10 mmol/L) for 1 h, then treated with berberine or AICAR. Cell lysates were subjected to Western blot analysis using antibody against UCP2 and b-
actin. (n=3; *p,0.05 vehicle vs. berberine or AICAR treatment, #p,0.05 cycloheximide vs. vehicle). E. Immunoblot analysis of UCP2 expression in
HUVECs transfected with NRF1 siRNA. HUVECs were transfected with control siRNA or NRF1 siRNA for 48 h, then treated with berberine for 2 h. Cell
lysates were subjected to Western blot analysis using antibodies against NRF1 and UCP2. The blot is a representative of three blots from three
independent experiments.
doi:10.1371/journal.pone.0025436.g006
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-/- mice [60] exhibited higher levels of ROS in macrophages
and muscle, respectively. Furthermore, mice with deleted LDL
receptor exhibited extensive HFD-induced atherosclerotic plaques
when they received bone marrow transplanted from UCP2
-/-
mice, and that phenotype was not observed when they received
bone marrow transplants from UCP2
+/+ mice [53]. Thus, these
findings support a key role for UCP2 in mice in mitigating oxidant
stress and inhibiting pathways that lead to the development of
atherosclerotic plaque [44].
We consistently found increased UCP2 expression associated
withdecreasedlevelsofoxidativestressmarkersinberberine-treated
ApoE
-/- mice. Conversely, decreased UCP2 expression was
observed to parallel increased inflammation and oxidative stress.
Indeed,ApoE
-/-/AMPKalpha2
-/-miceexhibitenhancedoxidative
stress with defective UCP2 expression. Accelerated aortic lesions in
ApoE
-/-/AMPK alpha 2
-/- mice are suppressed by the antioxidant
tempol (a cell-permeable nitroxide free radical that acts as a
radicalscavenger and nitric oxide spin trap) [49], indicating a
causative roleof ROS in aortic lesions in ApoE
-/-/AMPKalpha 2
-/-
mice. Thus, it is reasonable to speculate that increased expression
and activation of UCP2 by berberine play a major factor in
mitigating aortic lesions in vivo. The suggestive experiments with
cultured cells described here do not address directly whether
berberine-enhanced UCP2 expression can reduce oxidative stress
and atherosclerosis in vivo. Thus, further investigation is needed to
demonstrate this hypothesized in vivo role of UCP2.
Our published data [31] have demonstrated that production of
ROS is responsible for berberine-induced AMPK activation,
which is seemingly in conflict with the inhibitory effects of
berberine on ROS reported here. This apparent conflict might be
resolved by the concept of ‘‘ischemic preconditioning’’, in which
suboptimal concentrations of ROS activate the expression of
antioxidant genes or suppress the expression or activity of
oxidant-producing enzymes. For example, our published reports
showed that AMPK can suppress ROS production by suppress-
ing NAD(P)H oxidase [61] and increasing expression of
antioxidant genes such as MnSOD or UCP2 [36]. Recent
evidence indicating that AMPK activation reduces hyperglyce-
mia-induced mitochondrial ROS production was provided by
Kukidome et al., who showed that induction of MnSOD and
promotion of mitochondrial biogenesis occurs via activation of
the AMPK-PGC1a pathway in HUVECs [62]. Interestingly,
Brand’s group promoted the idea that O2
- itself activates UCP-2
by unspecified mechanisms from the matrix side of the
mitochondrion [63]. Although the molecular mechanisms might
be complex, it is reasonable to hypothesize that a ROS-AMPK-
UCP2 axis might be keys to maintaining vascular redox
homeostasis and functions.
In summary, we have demonstrated that berberine limits
aortic lesions in vivo via AMPK activation. In addition, the
reduction of aortic lesions by berberine appears to be mediated
by enhanced expression of UCP2, which suppresses oxidative
stress and vascular inflammation. The data presented here
support the concept that AMPK may be an important
therapeutic target for treating atherosclorosis and other cardio-
vascular diseases.
Figure 7. Mitochondrial biogenesis increase UCP2 expression in HUVECs treatment with berberine. A&B. Immunoblot analysis of
mitochondrial proteins in HUVECs. Confluent HUVECs were treated with berberine (A) or AICAR (B), and the mitochondrial fraction was isolated from
lysed cells using of mitochondrial isolation kit (Therm, Pockford) according to the manufacturer’s instructions. A Western blot of the mitochondrial
fraction was probed with antibodies specific for cytochrome C, cytochrome C oxidase II (COX II), and UCP2. The blot is representative of three blots
from three independent experiments. C. Effect of chloramphenicol on up-regulation of UCP2 by berberine. Confluent HUVECs were pretreated with
chloramphenicol (10 mmol/L), then treated with berberine for 2 h. Cell lysates were subjected to Western blot analysis using antibodies against UCP2
and b-actin. The blot is a representative of three blots from three independent experiments. D. Immunoblot analysis of UCP2 in berberine-induced
HUVECs transfection with mtTFA siRNA. HUVECs were transfected with control siRNA or mtTFA siRNA for 48 h, then treated with berberine for 2 h.
Cell lysates were subjected to Western blot analysis using antibodies against UCP2, mtTFA and b-actin. (n=3; *p,0.05 vehicle vs. berberine, #p,0.05
control siRNA vs. mtTFA siRNA). E. Time course of mtTFA expression. Confluent HUVECs were treated with berberine (10 mmol/L) for the indicated
times. Cell lysates were subjected to Western blot analysis using antibodies against mtTFA and b-actin. The blot is representative of three blots from
three independent experiments.
doi:10.1371/journal.pone.0025436.g007
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